Background: Pregabalin is a calcium channel α2δ ligand that modifies visceral hyper-
| INTRODUCTION
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterised by abdominal pain and symptoms of constipation, diarrhoea or both. The pain is associated or relieved by having a bowel movement and is associated with change in stool consistency or frequency. Several studies have shown that abdominal pain is one of the key drivers of health care seeking. 1, 2 Symptoms greatly impact patients' ability to go to school and/or work, 3 and health-related quality of life has been shown to be lower in IBS patients. 4 Visceral hypersensitivity is also a common feature observed in IBS patients. 5 Treatment options for managing IBS-related abdominal pain are available. 6 Antispasmodics as well as tricyclic antidepressants as neuromodulators are frequently utilised. Newer IBS therapies such as linaclotide, eluxadoline and a low FODMAP diet are also available. [6] [7] [8] However, these therapies are not effective for all patients, and patients and providers then struggle to improve pain without resorting to addictive therapies such as opioid drugs, which should almost never be prescribed for IBS pain. 6 Pregabalin is a structural derivative of the neurotransmitter, gamma-aminobutyric acid. It binds the α2δ subunit on voltage-dependent calcium channels on neurons expressed in the central nervous system. Pregabalin has known analgesic as well as anxiolytic effects. As such, it is FDA-approved for fibromyalgia as well neuropathic pain conditions such as herpetic neuralgia and diabetic neuropathy. Pregabalin has also been used to treat generalised anxiety disorder, and there is literature showing that it may help with other pain conditions such as post-operative pain and chronic pancreatitis. 9, 10 Data on pregabalin's effects on visceral pain and IBS are limited but suggest the drug does reduce gut visceral hypersensitivity. 11, 12 Because of its known effects on pain, we postulated that pregabalin would decrease bowel symptoms-particularly IBS-related abdominal pain or discomfort. As such, this study was conceived and designed with the aim to collect clinical data on pregabalin's effects on IBS symptoms.
| ME TH ODS
The study was approved by our Institutional Review Board. The trial was registered at clinicaltrials.gov (NCT00977197).
| Subjects
Subjects were English-speaking US residents aged 18-70 years who had a clinical diagnosis of IBS, met Rome III criteria for IBS and had at least three pain attacks a month of intensity exceeding 50 out of 100 as measured by a 10 cm visual analog scale. Participants were recruited through community, clinical and research advertisement.
Participants also had to experience one pain attack exceeding 50/ 100 in intensity during the 2 weeks screening period. 
| Study design
The study design was that of a randomised, double-blind, placebocontrolled and two-arm parallel group conducted at a single institution in the Upper Midwest as well as an associated health system site. The recruitment period was March 2010 through October 2014.
| Screening period
At the initial and only study visit, patients were screened for inclusion and exclusion criteria. If eligible, there was a pre-treatment 2 weeks screening period. Patients completed a daily symptom diary that included a rating of abdominal pain. If a patient experienced at least one pain attack with intensity equalling or exceeding 50 on a scale of 0-100, the patient was then randomised at week 0.
| Randomization and treatment phase
A dynamic allocation randomisation method 14 was used to randomise subjects to one of two treatment arms balanced on symptom subtype (constipation, diarrhoea, mixed) and fibromyalgia status (presence, absence) at week 0. Balancing on IBS subtype was performed to increase the likelihood of comparable distributions between treatment arms. Because pregabalin is an approved treatment for fibromyalgia and because this condition is a common comorbid condition with IBS, balancing on fibromyalgia status was performed to increase the likelihood of comparable distribution between treatment arms. We wanted symptom improvement to not be due to imbalanced representation and attributed to improvement in fibromyalgia symptoms. At the study start, randomisation schedules were generated by the statistician, and the schedules were concealed from the study team. At time of subject randomisation, the coordinator contacted the statistician with the gender, IBS subtype and fibromyalgia status and a study subject number was then provided. A prescription with study subject number was faxed to the research pharmacy. A research pharmacist dispensed study drugs in bi-weekly dose packs directly to the patient. Subjects, coordinators and co-investigators were blinded to treatment arm assignments. 
| Data management
Study data were collected and managed using REDCap electronic data capture tools hosted at Mayo Clinic. REDCap (Research Electronic Data Capture) is a secure, web-based application designed to support data capture for research studies, providing: (a) an intuitive interface for validated data entry; (b) audit trails for tracking data manipulation and export procedures; (c) automated export procedures for seamless data downloads to common statistical packages;
and (d) procedures for importing data from external sources. 22 All co-authors had access to the study data and had reviewed and approved the final manuscript.
| Study endpoints
The a priori primary endpoint for this study was the mean Bowel Symptom Scale (BSS) score for abdominal pain or discomfort over the last 4 weeks of treatment. Pre-specified secondary endpoints 
| Statistical analysis
An intention-to-treat analysis of covariance was used to analyse effects of treatment on quantitative endpoints, adjusting for age and gender and for IBS quality of life scores, baseline values. Missing values were imputed using the overall mean value for quantitative data;
responses were assumed to be "no" for the discrete endpoints. Analyses were repeated by IBS subtype (constipation-predominant IBS
[IBS-C]; diarrhoea-predominant IBS [IBS-D]; mixed type IBS [IBS-M]).
A P < 0.05 was considered statistically significant. 
| RESULTS

| Recruitment
In total, 85 of a goal of 100 eligible patients were recruited and randomised. Recruitment ceased due to slow subject recruitment. Fortyone were randomised to the pregabalin arm and 44 were randomised to the placebo arm. Nine subjects per arm dropped out during the study: seven discontinued for reasons unrelated to the study and four discontinued due to adverse events, four were lost to follow up, one discontinued due to lack of efficacy and two discontinued for non-compliance (Figure 1 ).
| Sample characteristics
Sample characteristics for 85 subjects are outlined in Table 1 
| Study outcomes
In comparing mean bowel symptoms scale pain or discomfort scores over weeks 9-12 ( Figure 2 ), subjects receiving pregabalin reported lower pain scores than those receiving placebo (25 [SD = 16] vs 42
[SD = 27], P = 0.008). Table 2 shows the mean bowel symptoms scale scores at weeks 9-12 and at week 12. In addition to subjects in the active treatment arm having better pain or discomfort BSS scores, their overall IBS, diarrhoea and bloating BSS scores were lower than in the placebo arm (P = 0.009, 0049 and 0.016 respectively). Findings were similar between the weeks 9-12 data compared with the end of treatment, week 12 BSS scores.
When evaluating adequate relief of IBS symptoms, 46% of patients receiving pregabalin reporting adequate relief for over 50% of weeks 9-12 compared to the 36% of the placebo arm, but this difference was not statistically significantly different (P = 0.35) (Figure 3) . When comparing the proportion of patients reporting greater than a 30 point change on a 100 point visual analog scale, 63% of pregabalin subjects vs 45% of placebo subjects met this criteria (P = 0.10).
Analyses were repeated by IBS subtype. Mean BSS scores at Irritable bowel syndrome quality of life scores at week 12 are shown in Table 3 . Overall IBS quality of life mean scores did not differ at week 12 between the pregabalin and placebo arm. Of the 
| Adverse events
Adverse events were collected from all individuals randomised.
Adverse events were common in both treatment groups. 28
(68%) of the pregabalin arm reported a side effect; 24 (55%) of the placebo arm reported a side effect (P = 0.19). The more common side effects are summarised in Table 4 . Gastrointestinal symptoms were common in both treatment arms, but did not differ between active and placebo arm, except for constipation, which was slightly more common in the pregabalin arm (P = 0.10). As anticipated, neurological symptoms-such as blurred vision, dizziness, altered sensorium-were more common in the pregabalin arm than the placebo arm. One subject died for reasons unrelated to the study.
| DISCUSSION
This clinical trial evaluated pregabalin's effect on IBS symptoms in IBS patients and suggests that pregabalin has beneficial effects on overall IBS symptoms as well as IBS-related abdominal pain, diarrhoea and bloating. Importantly, for our primary outcome evaluating its effect on abdominal pain and discomfort, patients receiving pregabalin reported lower pain scores than those receiving placebo (25 vs 42, P = 0.008). One of our secondary endpoints of a trend with a decrease in pain scores of at least 30 points also may support its efficacy on IBS-related abdominal pain (P = 0.10). The onset of symptom relief was rapid within the first week of treatment (data not shown) and persisted throughout the 12 weeks of treatment.
Pregabalin alters visceral sensation in animal models and in patients with IBS, and this may explain its mechanism of action. In the guinea pig, intrinsic primary afferent neurons express α2δ1 and pregabalin appeared to bind these neurons. 24 In rats, pregabalin appeared to decrease viscerosomatic and autonomic responses to colorectal distension. 11 In colonic mouse models of post-inflammatory visceral hypersensitivity, pregabalin significantly reduced colonic distention induced sensation. 25 Iturrino et al showed that a single 200 mg dose of pregabalin in healthy volunteers resulted in a 25% reduction in gas and pain sensation ratings in healthy volunteers. The first data in IBS patients was collected in a study by Houghton et al. 12 In this study, 26 IBS patients underwent rectal barostat testing before and after 3 weeks of pregabalin or placebo.
Patients receiving pregabalin reported increased sensory thresholds for first sensation, desire to defecate and pain. Furthermore, increased rectal compliance was also seen. A trend for lower average daily pain scores in the pregabalin vs placebo arm was seen (P = 0.068). However, pregabalin's impact on other IBS symptoms was not collected. More recently, Iturrino studied the effects of a single 200 mg dose on symptoms and colonic sensation thresholds and compliance in 18 patients with IBS-C and observed no effects on these outcomes. 26 We believe our study results complement the findings of these previous studies, but enhancements and strengths of our study include that our study sample size was larger, treatment duration was longer, our study focused on IBS symptoms rather than GI physiology and our study sample included all IBS subtypes.
The maximal benefit appeared to be for diarrhoea-predominant IBS and mixed-typed IBS, but not constipation-predominant IBS in the subgroup analysis. In the sample overall, pregabalin did not appear to impact constipation scores. However, our constipationpredominant IBS subgroup was the smallest of the three groups, so it is conceivable that an effect would have been observed had a larger group been included. However, this lack of effect may be a real finding in that constipation is a known side effect of pregabalin, and T A B L E 2 Mean Bowel Symptom Scale (BSS) scores at weeks 9-12 and at week 12 (21) 43 (28) 0.016* Pain, overall IBS, diarrhoea and bloating scores were lower in the active treatment arm for the last 4 weeks of treatment as well as during the last week of treatment.* P < 0.05.
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Adequate relief -weeks 9-12 is not clear that pregabalin will improve quality of life.
Emphasising the limitations of this study is important. This study sample size from this single centre trial was not large-85 were randomised. We had hoped to recruit 100 subjects, but recruitment was slow and the study was terminated early. Our study intentionally targeted patients with moderate-severe pain to decrease the likelihood of a floor effect. However, for that same reason, we found it difficult to recruit patients in pain seeking immediate symptom relief. This study also did not utilise the FDA outcomes for IBS. This study was conceived and designed prior to the FDA guidance document. 23 As such, although we can provide data on patients reporting a 30 point reduction in pain from baseline (66% vs 45%, P = 0.10),
we cannot provide data on improvement in number of complete, spontaneous bowel movements in our constipation patients nor can we provide data on the change in days with fewer bowel movements without Bristol 6 or 7 consistency stools. Based on our recruitment study, results should be generalisable to community IBS patients as well as referral-level IBS patients; it's applicability to those with mild or severe pain is not known.
Abdominal pain is often cited as a major driver for patients with IBS to seek medical care. 27 Treatment options for IBS-related pain include antispasmodics, peppermint oil, 28 probiotics 29 and antidepressants. 30 A systematic review of IBS treatments also suggests that linaclotide has beneficial effects on IBS pain. 6 Lubiprostone decreases pain, bloating and improves bowel habit in those with IBS with constipation. 31 Eluxadoline was more effective than placebo in reduction of abdominal pain and improvement in stool consistency. 7, 32 For IBS with diarrhoea, rifaximin may improve IBS. 33 However, these therapies are very specific to IBS subtype. Newer IBS therapies for IBS also provide promise for IBS pain management.
Dietary interventions such as the low FODMAP diet show promise.
Halmos et al. performed a randomised trial comparing the effects of a low FODMAP diet compared to a traditional Australian diet and observed that patients of all IBS subtypes had lower overall symptom scores on the low fermentable carbohydrate diet including pain. 34 However, firm conclusions on the benefits of this diet cannot be made due to the paucity of unbiased randomised trials. 35 Nonetheless, many patients find incomplete symptom relief with conventional interventions. Because this trial shows efficacy in IBS-related quality of life-overall as well as the eight domains-did not differ between the two treatment arms at the end of treatment.
patients with moderate-severe pain, we speculate that pregabalin may be useful to non-constipated IBS patients who fail other conventional therapies.
Our study provides novel and important data suggesting a posi- 
